Lenalidomidă Grindeks (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex. This interaction triggers the ubiquitination and proteasomal degradation of transcription factors Ikaros and Aiolos, leading to anti‑angiogenic activity, modulation of immune responses, and direct inhibition of malignant cell proliferation.

The dosing regimen for lenalidomide is individualized and must be determined by the prescribing healthcare professional based on the specific indication, disease stage, renal function, and patient tolerance. No standardized dose is provided here.

Lenalidomidă Grindeks is classified as pregnancy category X, meaning it is contraindicated during pregnancy because of known fetal toxicity. It should not be used by breastfeeding mothers, and effective contraception is required for women of child‑bearing potential throughout treatment and for a defined period after discontinuation.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Both lenalidomide and thalidomide belong to the immunomodulatory imide drug (IMiD) class, but lenalidomide is more potent, has a different safety profile, and generally causes fewer peripheral neuropathy events. Lenalidomide also exhibits stronger anti‑angiogenic and immune‑stimulating effects, making it the preferred choice for many of the approved indications.

Store Lenalidomidă Grindeks below 25 °C in its original packaging. Keep the product away from moisture, heat and direct sunlight. Do not store in the bathroom or near a kitchen sink, and ensure the container is tightly closed when not in use.

Lenalidomidă Grindeks is taken orally as a tablet. It may be swallowed with or without food, according to the prescriber’s instructions. Patients should follow the dosing schedule provided by their healthcare professional and avoid crushing or chewing the tablet unless specifically advised.

Serious risks include severe neutropenia, thrombocytopenia, venous thromboembolism, secondary primary malignancies, and severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for blood‑count abnormalities and signs of clotting, and any new rash or unexplained symptoms should be reported promptly.

Lenalidomidă Grindeks should not be used by pregnant women, individuals with known hypersensitivity to lenalidomide or any component of the formulation, and patients with severe renal impairment unless dose adjustments are made under medical supervision. Caution is also advised for patients with a history of thromboembolic events.